Great Report

Just downloaded a fantastic report from IQVIA on the multiplicity of immunotherapeutics.  The site states:

A record number of new oncology drugs has been approved in recent years, bringing new treatment options to patients. However, despite robust levels of pipeline activity, oncology remains a challenging area for research and development. This report examines the productivity and output of the oncology pipeline, new treatment mechanisms, and which patients will likely benefit from new therapies. Our research brings into focus the amount spent on oncology medicines globally, clinical trial activity, complexity and success, and the outlook through 2023. The report also addresses shifts in therapy use with the emergence of immuno-therapies, Next-Generation Biotherapeutics and biosimilars.

Yet there are multiple new dimensions also expected:

1. Other checkpoints and their inhibiting actions

2. The tumor micro environment and its inhibiting capacity

3. The macrophage inhibiting actions

just to name a few.